Advertise on podcast: CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases

Please visit answersincme.com/QRE860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Theresa W. Guilbert, MD, MS. In this activity, an expert in childhood asthma discusses the use of biologics for moderate to severe pediatric asthma. Upon completion of this activity, participants should be better able to: Identify the impact of type 2 inflammation on lung function in pediatric patients with asthma; Recognize best practices for incorporating biologics into the treatment of type 2 inflammatory pediatric asthma; and Review the clinical profiles of biologic therapies for type 2 inflammatory asthma in pediatric patients. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/TZA860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by James E. Galvin, MD, MPH. In this activity, an expert in Alzheimer’s disease (AD) discusses treatment of early AD with anti-amyloid therapies. Upon completion of this activity, participants should be better able to: Review the latest advances in anti-amyloid therapies for the treatment of early Alzheimer’s disease (AD; Assess the current evidence on anti-amyloid therapies, including maintenance strategies, for the treatment of early AD; and Outline strategies to integrate the latest advances in anti-amyloid therapies to practice to improve long-term outcomes for patients with early AD.

Please visit answersincme.com/860/MED-RESP-04317-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Cecelia Damask, DO; Zara M. Patel, MD; Maria Colandrea, DNP, NP-C, CORLN, FAANP; and Dan Shaltanis. In this activity, experts in chronic rhinosinusitis with nasal polyps discuss the latest evidence and practical strategies for optimizing the use of biologic therapies and delivering patient-centered care. Upon completion of this activity, participants should be better able to: Review guideline recommendations for the use of biologic therapies to treat patients with chronic rhinosinusitis with nasal polyps (CRSwNP); Differentiate among biologic therapies for patients with CRSwNP based on clinical evidence; and Outline strategies to optimize the holistic management of CRSwNP.

Please visit answersincme.com/JKK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Alison J. Birtle, FRCP, FRCR, MD; and Niklas Klümper, MD. In this activity, experts in oncology discuss systemic therapies for locally advanced and metastatic urothelial carcinoma. Upon completion of this activity, participants should be better able to: Assess the evidence for recommended systemic treatment regimens for patients with LA/mUC in the context of treatment guidelines; Propose appropriate patient assessment strategies to guide systemic therapy decisions; and Formulate individualized treatment strategies to optimize outcomes for patients with LA/mUC using recommended first-line systemic treatments.

Please visit answersincme.com/AQE860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Nirmala Gonsalves, MD, AGAF, FACG. In this activity, an expert in esophageal gastroenterology, discusses strategies for pharmacological treatment of eosinophilic esophagitis (EoE). Upon completion of this activity, participants should be better able to: Specify the current guideline recommendations for the pharmacologic treatment of eosinophilic esophagitis (EoE); Formulate personalized strategies to use approved pharmacologic options during initiation and maintenance phases of EoE management; and Apply multidisciplinary strategies to optimize long-term management of patients with EoE using approved pharmacologic treatments.

Please visit answersincme.com/WWD860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Peter Lio, MD, FAAD; Sarah L. Chamlin, MD; and Heather Moery. In this activity, experts in pediatric atopic dermatitis discuss earlier use of systemic therapy to improve long-term disease control and patient-centered outcomes. Upon completion of this activity, participants should be better able to: Identify the need for systemic therapy among pediatric patients with moderate-to-severe atopic dermatitis (AD); Recognize pediatric patients with moderate-to-severe AD for whom biologic therapy is an appropriate, evidence-based option; Review shared decision-making considerations regarding biologic therapy for pediatric patients with moderate-to-severe AD; and Integrate strategies to optimize biologic treatment for pediatric patients with moderate-to-severe AD.

Please visit answersincme.com/860/2026-MC-001884-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Marc Serota, MD; Kristin Sokol, MD, MS, MPH; and Michelle Tarbox, MD. In this activity, experts in chronic spontaneous urticaria (CSU) discuss strategies to reduce diagnostic delays and how to personalize care beyond antihistamines. Upon completion of this activity, participants should be better able to: Recognize the impact of delayed diagnosis on disease control in patients with CSU; Review key inflammatory pathways—including type 2 inflammation—in CSU pathogenesis and how targeted therapies modulate them; Assess the latest clinical data for targeted therapies for the treatment of CSU; and Apply evidence-based strategies to personalize the management of antihistamine-refractory CSU.

Please visit answersincme.com/TNM860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Richard Kim, MD. In this activity, an expert in oncology discusses when and how to sequence later-line and chemotherapy-free therapies in metastatic colorectal cancer (mCRC). Upon completion of this activity, participants should be better able to: Evaluate factors influencing a treatment switch from cytotoxic agents for patients with stable metastatic colorectal cancer (mCRC); Formulate practical approaches for transitioning from chemotherapy to tyrosine kinase inhibitor (TKI) treatment in later-line settings for patients with mCRC; and Describe strategies to prolong chemotherapy-free disease control with TKIs.

Please visit answersincme.com/BJN860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Rajesh Gandhi, MD. In this activity, an expert in infectious diseases discusses novel oral antiretroviral therapy (ART) for the management of human immunodeficiency virus (HIV). Upon completion of this activity, participants should be better able to: Recognize the rationale for novel oral ART regimens in the management of virologically suppressed HIV infection; Review the clinical impact of novel emerging oral ART regimens for patients with virologically suppressed HIV infection; and Formulate patient-centered strategies for optimizing the personalized management of oral ART for patients with virologically suppressed HIV infection.

Please visit answersincme.com/DDT860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Robert Haddad, MD. In this activity, an expert in medical oncology discusses locally advanced head and neck squamous cell carcinoma (LA HNSCC). Upon completion of this activity, participants should be better able to: Discuss the clinical implications of the latest data for approved and recommended regimens for resectable LA HNSCC in the pre- and postoperative settings; Outline strategies to integrate immunotherapy into pre- and postoperative settings for resectable LA HNSCC, in the context of conventional treatment; and Apply multidisciplinary team approaches to effectively manage patients with LA HNSCC across pre- and postoperative treatment phases.

Please visit answersincme.com/TNH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Nick H. Kim, MD and Vallerie V. McLaughlin, MD. In this activity, experts in cardiovascular medicine and pulmonology discuss pulmonary arterial hypertension (PAH). Upon completion of this activity, participants should be better able to: Recognize the importance of treatment escalation for appropriate patients with PAH; Design risk-based treatment escalation plans for patients with PAH; Review the clinical impact of guideline-recommended therapies for risk-based treatment escalation in PAH; and Propose practical considerations to enhance outcomes for patients with PAH requiring treatment escalation.

Please visit answersincme.com/860/MED-GST-04054-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Joy W. Chang, MD, MS; Robbie Pesek, MD; and Sarah Enslin, PA-C, MS. In this activity, multidisciplinary experts in pediatric and adult eosinophilic esophagitis (EoE) highlight updated management guidelines and provide case-based insights on implementing guideline-concordant pharmacologic therapies in real-world practice. Upon completion of this activity, participants should be better able to: Identify current guideline recommendations for the pharmacologic treatment of EoE; Specify how patient, disease, and treatment factors impact treatment selection for EoE; and Integrate guideline-recommended pharmacologic therapies into individualized care for patients with EoE. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/MRQ860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Alexandra K. Golant, MD; Peter Lio, MD, FAAD; and Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP. In this activity, experts in dermatology discuss the OX40L pathway and its potential role in the treatment of moderate-to-severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Identify the rationale for targeting the OX40/OX40 ligand (OX40L) pathway in the treatment of moderate-to-severe atopic dermatitis (AD); Assess the evidence on efficacy outcomes and safety profiles of the emerging OX40/OX40L inhibitors in AD, including quality of life (QoL) impact; Integrate QoL assessments into shared decision-making with patients who have moderate or severe AD; and Outline strategies for enhancing the multidisciplinary management of moderate-to-severe AD.

Please visit answersincme.com/860/IME_2025_00013162-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Toby Maher, MB, MSc, PhD, FRCP; and Justin Oldham, MD, MS. In this activity, experts explore advances in ILD care, including personalized, multidisciplinary approaches to integrate novel antifibrotic therapy and enhance patient engagement. Upon completion of this activity, participants should be better able to: Recognize the rationale for novel antifibrotic therapy in interstitial lung disease (ILD); Apply the latest clinical data on novel antifibrotic therapy to therapeutic decision-making in ILD; and Outline multidisciplinary strategies to enhance the care of patients with ILD who are receiving antifibrotic therapies.

Please visit answersincme.com/CNW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Stephen V. Liu, MD and Amber Fake. In this activity, an expert in non–small-cell lung cancer (NSCLC) discusses the evolving patient-centered management of HER2-mutant NSCLC, focusing on the use of HER2-targeted TKIs. Upon completion of this activity, participants should be better able to: Describe how HER2-targeted TKIs may address the clinical needs for diverse patient populations with HER2-mutant NSCLC; Implement evidence-based molecular profiling to identify HER2 alterations in NSCLC; Evaluate the clinical evidence of current and emerging HER2-targeted treatments; and Integrate shared decision-making strategies to align preferences for patients with HER2-mutant NSCLC.